45 results about "Atherosclerotic cardiovascular disease" patented technology

The present invention identifies two circulating proteins that have been newly identified as being differentially expressed in atherosclerosis. Circulating levels of these two proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

The present invention identifies circulating proteins that are differentially expressed in atherosclerosis. Circulating levels of these proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Compounds comprising multi-vitamins, zinc and an anti-platelet aggregating agent for the treatment of atherosclerotic cardiovascular disease (ASCVD) are disclosed. The compounds are provided in dosage form, and preferably include selected amounts of ascorbic acid, folic acid, vitamin E, vitamin B6 and vitamin B12. The anti-platelet aggregating agent preferably comprises aspirin. A protective coating is preferably provided between the aspirin and the other vitamin and mineral constituents. The dosages are effective in the treatment of ASCVD, and possess extended shelf lives.

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.

New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

New pyridine-based compounds of Formula I, compositions, and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3-mediated disorders in vivo are provided. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

A system for treating atherosclerotic cardiovascular disease and cardiac valve dysfunction comprises delivering one or more calcium chelating agents locally to a treatment site. One aspect of the invention provides a method including delivering a nano-particulate calcium chelating agent into a vascular wall. Another aspect of the invention provides a method and device for forming a sealed chamber around a cardiac valve, releasing one or more calcium chelating agents into the sealed chamber and decalcifying a cardiac valve in need thereof.

The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.

The invention discloses a baicalein derivative drug which can be used for the prevention and treatment of metabolic syndrome, obesity, type 2 diabetes and atherosclerotic cardiovascular disease. The baicalein derivative can increase the metabolic activity for the prevention and treatment of metabolic syndrome, obesity, type 2 diabetes and atherosclerotic cardiovascular disease by controlling and activating the activity of single adenylate activated protein kinase.

The assay of soluble endothelial protein C receptor (sEPCR) is useful to predict cardiovascular disease, particularly atherosclerotic cardiovascular disease (ASCVD). An assay for sEPCR is therefore useful to identify individuals at risk of developing ASCVD. An sEPCR ELISA assay is particularly useful for this purpose. Elevated sEPCR is indicative of an increased risk of developing cardiovascular disease.

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.

New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

The present invention provides a piece of semiquantitative detecting oxide low-density lipoprotein (OX-LDL) colloid selenium reagent paper, which can capture antigen quantity according to OX-LDL monoclonal antibody to create a relation between color and standard OX-LDL and diagnose that content of OX-LDL in human blood plasma is higher than, lower that or equal to standard OX-LDL quantity in human blood plasma, thus realizing early auxiliary diagnosis to ASCVD. The present invention has the advantages of convenience, quickness, sensitivity, specificity and economic efficiency, rejects specified instruments and equipments and is conveniently taken.

The invention discloses application of miR-320a and its antisense nucleotide respectively in risk assessment / diagnosis of atherosclerotic cardiovascular and cerebrovascular diseases and prevention and treatment of atherosclerotic cardiovascular and cerebrovascular diseases. The inventor conducts a lot of experimental study to prove that: the miR-320a level changes (rises) in blood plasma (or serum) of high-risk groups of atherosclerotic cardiovascular and cerebrovascular diseases (atherosclerosis, coronary heart disease, myocardial infarction and stroke) and coronary heart disease, and the miR-320a level rise can induce atherosclerosis, inflammatory state and blood-lipid metabolic disorder obviously; and miR-320a's antisense nucleotide anti-miR-320a can alleviate, prevent and treat the atherosclerotic cardiovascular and cerebrovascular diseases and relevant disorder states. According to the invention, finally conclusions are obtained as the following: (1) miR-320a can be taken as a novel target for drugs, the nucleotide anti-miR-320a can be used for preventing and treating atherosclerotic cardiovascular and cerebrovascular diseases (such as atherosclerosis, coronary heart disease, myocardial infarction and stroke and the like); and (2) the peripheral blood miR-320a level can be adopted as a new biomarker, and its expression level can be detected for predicting and assessing the risk of atherosclerotic cardiovascular diseases or assisting in diagnosing already existing atherosclerotic cardiovascular diseases. Also, the fluorescent quantitative PCR (polymerase chain) technology can be employed to detect the expression level of miR-320a in patient peripheral blood so as to assist diagnosis of the atherosclerotic cardiovascular diseases.

New carbocyclic compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease, other neurodegenerative disorders, such as Parkinson's disease and Huntington's disease, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Novel brain targeted low molecular weight, hydrophobic antioxidants and use of antioxidants in treatment of central nervous system neurodegenerative disorders such as Parkinson's, Alzheimer's and Creutzfeldt-Jakob's diseases and in treatment of conditions of peripheral tissues, such as acute respiratory distress syndrome, amyotrophic lateral sclerosis, atheroscierotic cardiovascular disease and multiple organ dysfunction, in which oxidants are overproduced.

Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine N-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value. The test subject's risk of having cardiovascular disease is then characterized as higher if the levels of the choline-related trimethylamine-containing compound are higher than the control value. Also provided are methods of identifying a subject at risk of experiencing a complication of atherosclerotic cardiovascular disease, and methods of evaluating the efficacy of a cardiovascular therapeutic agent in a subject with cardiovascular disease using levels of choline-related trimethylamine-containing compounds.

New pyrimidine or pyridine based compounds, having the structure(I), compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder immunodeficiency or cancer.

The invention discloses an application of 2-cycloxyl substituted or cyclothio substituted hydroxyacetophenone in treatment of metabolic diseases. In particular, the invention relates to an application of a compound as shown in general formula (I) in preparation of medicaments for preventing or treating metabolic diseases. Wherein X is selected from H, NO2, or OH; Y is selected from H or OH; Z is selected from O or S; A ring is selected from an alicyclic group, a heteroalicyclic group, an aryl, and a heteroaryl; Z and R can be connected with any appropriate connection site on the A ring; R represents one or more than one substituent. The metabolic diseases comprise metabolic syndrome, obesity, diabetes mellitus, hyperglycemia, diabetic nephropathy, hyperlipidemia, hypertension, coronary heart diseases, atherosclerotic cardiovascular diseases, cardio-cerebrovascular diseases, and diseases of the liver, the kidney, and the thyroid as a result of the above.

Disclosed are a biomarker, the use of the biomarker in predicting the risk of atherosclerotic cardiovascular disease or related disorder thereof, and a method of predicting the risk of atheroscleroticcardiovascular disease or related disorder thereof.

The invention discloses application of miR-320a and its antisense nucleotide respectively in risk assessment / diagnosis of atherosclerotic cardiovascular and cerebrovascular diseases and prevention and treatment of atherosclerotic cardiovascular and cerebrovascular diseases. The inventor conducts a lot of experimental study to prove that: the miR-320a level changes (rises) in blood plasma (or serum) of high-risk groups of atherosclerotic cardiovascular and cerebrovascular diseases (atherosclerosis, coronary heart disease, myocardial infarction and stroke) and coronary heart disease, and the miR-320a level rise can induce atherosclerosis, inflammatory state and blood-lipid metabolic disorder obviously; and miR-320a's antisense nucleotide anti-miR-320a can alleviate, prevent and treat the atherosclerotic cardiovascular and cerebrovascular diseases and relevant disorder states. According to the invention, finally conclusions are obtained as the following: (1) miR-320a can be taken as a novel target for drugs, the nucleotide anti-miR-320a can be used for preventing and treating atherosclerotic cardiovascular and cerebrovascular diseases (such as atherosclerosis, coronary heart disease, myocardial infarction and stroke and the like); and (2) the peripheral blood miR-320a level can be adopted as a new biomarker, and its expression level can be detected for predicting and assessing the risk of atherosclerotic cardiovascular diseases or assisting in diagnosing already existing atherosclerotic cardiovascular diseases. Also, the fluorescent quantitative PCR (polymerase chain) technology can be employed to detect the expression level of miR-320a in patient peripheral blood so as to assist diagnosis of the atherosclerotic cardiovascular diseases.

New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

The invention relates to a drug for lowering blood lipid. A structure of the drug is shown as a formula (1) to a formula (4) (please see the specification for the formula (1) to the formula (4)). Theinvention further relates to following application of a compound shown in the formula (1) to the formula (4) to: (1) preparation of drugs for treating atherosclerotic cardiovascular diseases; (2) preparation of drugs for adjusting blood glucose metabolism, wherein blood glucose metabolism adjusting refers to lowering of blood glucose, lowering of glycated serum protein, and lowering of glycated albumin; (3) preparation of drugs for reducing liver lipid accumulation and preventing fatty liver; and (4) preparation of preparations for inhibiting the expression of PCSK9 at the genetic level and improving the expression of LDLR.

A composition for delivering a cargo to the cytoplasm of a cell, wherein the cargo treats Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus Type 1 and Type 2, Atherosclerotic Cardiovascular Disease, and Alpha 1 Antitrypsin Deficiency. In another embodiment, the composition comprises: an exosome; cargo located inside the exosome, wherein the cargo comprises short interference RNA (siRNA) that depletes sodium-glucose linked transporter active sites. In another embodiment, the composition comprises: an exosome; cargo location inside the exosome, wherein the cargo corrects the missense SERPINA1 mutation from ‘Z’ to ‘M’.

Bicyclic based compounds of the formula (I), compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and a treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

This invention relates to a genus of compounds, represented by the formula (I) diagrammed below, wherein the meanings of R1, R2, R3, R4, R5, R6, R7, R8, D and n are indicated therein, which are inhibitors of cathepsin K. These compounds are useful for treating or preventing atherosclerosis and atherosclerotic cardiovascular disease.